Volume 11 Issue 326
Published - 14:00 UTC 08:00 EST 10-Dec-2009 
Next Update - 14:00 UC 08:00 EST 11-Dec-2009

Editor: Susan K. Boyer, RN
Vidyya.
All rights reserved.




  

 




Potential cancer drug may offer new hope for asthma patients

(10 December 2009: VIDYYA MEDICAL NEWS SERVICE) -- A drug being tested to treat cancer could also help patients suffering from asthma, research has suggested.

Scientists at the University of Edinburgh found that the drug R-Roscovitine helps to kill certain immune cells which can exacerbate symptoms associated with asthma.

The findings could lead to an alternative way to treat asthma in patients who are resistant to steroids, which are commonly used in asthma treatments.

Researchers studied the effect that the drug had on immune cells known as eosinophils

Eosinophils, found in the lungs and airways, help the body fight off parasitic infection. However, too many uncontrolled eosinophils can damage other cells that line the lung, contributing to inflammatory conditions such as asthma.

Researchers found that use of the drug caused the eosinophil cells to undergo a form of cell death known as apoptosis, a natural process where unwanted cells are removed from the body.

Professor Adriano Rossi, of the Centre for Inflammation Research at the University of Edinburgh who directed the study, said: "Steroids are commonly used to treat asthma but can have unwanted side-effects, while some asthma patients are also resistant to steroid treatment. It may well be that use of a drug, such as R-Roscovitine, or one that works in a similar same way, could offer an alternative to steroids, or be used in conjunction with steroid treatment for asthma patients."

Return to Vidyya Medical News Service for 10 December 2009

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.